
How Can Genomics Guide Decision-Making in the Application of Immunotherapy?

Colin C. Pritchard MD, PhD University of Washington, Dept. of Lab Medicine Jan. 26, 2018 ASCO-SITC


PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

Immunotherapy




PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.





PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.


Mismatch DNA Repair (MMR)




MMR Deficiency Detection Methods


- Immunohistochemistry (protein expression)
- MSI by PCR capillary electrophoresis
- MSI by NGS
- MMR gene tumor sequencing
- Total mutation burden (not specific to MMR)


PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.












Presented By Colin Pritchard at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Mismatch Repair By IHC




PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

What is Microsatellite Instability?


- Caused by loss of mismatch repair function
- Short repetitive tracks of DNA (microsatellites) are mutated throughout genome
- Typically inferred from only 5 loci selected for optimal performance in colorectal cancer

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.


MSI by PCR (Promega 5-marker)



MSI by Next-Generation Sequencing (example: mSINGS)




Landscape of MSI Between Cancers



PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

⁰ Presented by:

MSI Patterns Are Not The Same Between Cancer Types



Why Might Cancer-Specific Differences in MSI Pattern Matter? False Negatives

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

Presented By Colin Pritchard at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Comparison of Current MMR Methods

Method	Clinical Availability	Cost	Turnaround Time	Sensitivity
MMR IHC	Wide	Lower	Fast	Only established in for colon cancer
MSI- PCR	Wide	Lower	Slower	Only established in for colon cancer
MSI- NGS	Limited	Moderate	Slower	Likely superior to other methods, more data needed

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

Presented By Colin Pritchard at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Total Mutation Burden as Biomarker


- Hypermutation correlates well with MMR deficiency
- May capture more PD1/PDL1i responsive cases than MSI
- More data needed
- Difficult to standardize: Calibration materials needed

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM #ImmunoOncl8
Slides are the property of the author. Permission required for reuse.

Presented By Colin Pritchard at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Presented

Total Mutation Burden: Mechanisms



Campbell et al. (2017) Cell PMID: 29056344

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

Presented By Colin Pritchard at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Conclusions/Take-Home Points

- MSI is likely to predict checkpoint blockade responses
- Current MSI-PCR methods are not well-validated beyond colon cancer, but are nonetheless being used in many cancer types
- MSI patterns differ between cancer types, cancer-tailored MSI methods may be needed to improve sensitivity
- MSI by NGS is robust and likely superior to traditional methods due to the large number of loci that can be sampled
- Total Mutation Burden is a promising biomarker for checkpoint blockade response, calibrator materials will assist with standardization

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

Presented By Colin Pritchard at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium



Thank You!

- Steve Salipante
- Jennifer
 Hempelmann
- Pete Nelson
- Heather Cheng
- Bruce
 Monigomery
- Johann de Bono
- Joaquin Mateo
- Mallory Beightol
- · Tom Walsh
- Mary-Claire King
- Jay Shendure

PRESENTED AT: ASCO-SITC CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM | #ImmunoOnc18 Slides are the property of the author. Permission required for reuse.

- Evan Yu
 - Heather Hampel
- Sisi Haraldsdottir
- Albert de la
 - Chappelle
- Mark Rubin
- Gabi Chiorean
- Mike Schweizer
 - **Christy Smith**
 - Tamara Lotan
 - Emmanuel
 - Antonarakis

Funding

Pacific Northwest Prostate Cancer •••• SPORE

PROSTATE CANCER FOUNDATION Accelerating the world's most promising research

Congressionally Directed Medical Research Programs

STAND

Department of Defense